Ardelyx, Inc. develops medicines for gastrointestinal and cardiorenal therapeutic areas. The companys lead product candidate is tenapanor for irritable bowel syndrome with constipation. Other product candidates include XPHOZAH, RDX013, and RDX020 for various kidney and heart-related conditions. XPHOZAH is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical, and Knight Therapeutics for tenapanor development and commercialization. Ardelyx was formerly known as Nteryx, Inc. and changed its name in June 2008. Headquartered in Waltham, Massachusetts, the company was incorporated in 2007.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 100.0 |